<DOC>
	<DOCNO>NCT00762658</DOCNO>
	<brief_summary>To investigate dose-response relationship , antipsoriatic efficacy safety different concentration topical formulation AN2728 patient psoriasis vulgaris</brief_summary>
	<brief_title>A Phase I Study Assess Novel Ointment Psoriasis Plaque Test</brief_title>
	<detailed_description>The study perform 12 male subject stable psoriatic plaque . The study preparation comparators test observer-blind . Treatments randomly assign test field . All subject receive treatment , intraindividual comparison treatment . Altogether six test field examine per subject ( three active AN2728 ointment different concentration : 5 % , 2 % 0.5 % , active ingredient-free vehicle , market corticoid preparation market topical immunomodulator ) . The test field treat occlusively study period 12 day . A topical application approximately 200 uL assign intervention administer per treatment , total 10 treatment 12-day treatment period .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<criteria>male subject age 18 year old ; subject psoriasis vulgaris chronic stable phase stable plaque area sufficient six treatment field ; physical examination must without disease finding unless investigator considers abnormality irrelevant outcome study ; write informed consent obtain . subject require systemically acting medication treatment psoriasis , might counter influence study objective , e.g . corticosteroid , cytostatics ; local treatment antipsoriatics ( except salicylic acid vaseline ) 4 week precede study ( corticosteroid 8 week ) ; systemic treatment antipsoriatics three month precede study ; treatment systemic locally act medication might counter influence study aim ( e.g . glucocorticosteroids , MAO inhibitor , antiepileptic drug , antipsychotic drug ) medication know provoke aggravate psoriasis , e.g . Î²blocker , antimalarial drug within two week begin study study ; know allergic reaction active ingredient component study preparation comparators ; evidence drug abuse ; UVtherapy within four week begin study ; symptom clinically significant illness may influence outcome study four week study ; participation another clinical trial involve pharmaceutical product four week precede study ; opinion investigator physician perform initial examination patient participate study , e.g . due probable noncompliance inability understand study give adequately inform consent . subject institutionalized legal regulatory order .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Plaque Type Psoriasis</keyword>
	<keyword>Topical</keyword>
</DOC>